Getting FDA authorization for an Expanded Access Program is a big step, especially with EDNOC on board. Targeting tough cancers like triple-negative br---t and pancreatic shows they’re going after real unmet needs. Feels like they’re laying solid groundwork for broader radioligand therapy adoption. I’m holding tight, I truly think this could be just the beginning.
There are no replies in this thread yet. Be the first to post a reply below: